Paper40242588
Recent Advances in the Development of Sigma Receptor (Radio)Ligands and Their Application in Tumors.
Wang T and 3 others. ACS Pharmacol Transl Sci, 2025. Cited by 5 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Recent Advances in the Development of Sigma Receptor (Radio)Ligands and Their Application in Tumors. Papers, record 40242588. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40242588
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Recent Advances in the Development of Sigma Receptor (Radio)Ligands and Their Application in Tumors.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References269
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28,280,965 | Radiosynthesis and First-In-Human PET/MRI Evaluation with Clinical-Grade [18F]FTC-146. | Mol Imaging Biol | 2017 | https://conductscience.org/library/papers/28280965 | PubMed |
| 2 | 33,007,549 | Fluorinated 2-Arylcyclopropan-1-amines - A new class of sigma receptor ligands. | Bioorg Med Chem | 2020 | https://conductscience.org/library/papers/33007549 | PubMed |
| 3 | 22,784,008 | Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862). | J Med Chem | 2012 | https://conductscience.org/library/papers/22784008 | PubMed |
| 4 | 22,292,588 | S2R(Pgrmc1): the cytochrome-related sigma-2 receptor that regulates lipid and drug metabolism and hormone signaling. | Expert Opin Drug Metab Toxicol | 2012 | https://conductscience.org/library/papers/22292588 | PubMed |
| 5 | 32,318,621 | A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study. | Alzheimers Dement (N Y) | 2020 | https://conductscience.org/library/papers/32318621 | PubMed |
| 6 | 28,315,274 | Role of σ1 Receptors in Learning and Memory and Alzheimer's Disease-Type Dementia. | Adv Exp Med Biol | 2017 | https://conductscience.org/library/papers/28315274 | PubMed |
| 7 | 33,233,619 | Sigma-2 Receptor-A Potential Target for Cancer/Alzheimer's Disease Treatment via Its Regulation of Cholesterol Homeostasis. | Molecules | 2020 | https://conductscience.org/library/papers/33233619 | PubMed |
| 8 | 37,691,601 | Diastereoselective synthesis and structure-affinity relationships of σ1 receptor ligands with spirocyclic scaffold. | Org Biomol Chem | 2023 | https://conductscience.org/library/papers/37691601 | PubMed |
| 9 | 23,922,215 | Sigma-2 receptor ligands and their perspectives in cancer diagnosis and therapy. | Med Res Rev | 2014 | https://conductscience.org/library/papers/23922215 | PubMed |
| 10 | 16,891,467 | Cyclohexylpiperazine derivative PB28, a sigma2 agonist and sigma1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer. | Mol Cancer Ther | 2006 | https://conductscience.org/library/papers/16891467 | PubMed |
| 11 | 30,040,970 | Imaging sigma receptors in the brain: New opportunities for diagnosis of Alzheimer's disease and therapeutic development. | Neurosci Lett | 2019 | https://conductscience.org/library/papers/30040970 | PubMed |
| 12 | 16,595,947 | Synthesis and in vitro evaluation of iodinated derivatives of piperazine as a new ligand for sigma receptor imaging by single photon emission computed tomography. | Chem Pharm Bull (Tokyo) | 2006 | https://conductscience.org/library/papers/16595947 | PubMed |
| 13 | 38,399,380 | [18F]Fluspidine-A PET Tracer for Imaging of σ1 Receptors in the Central Nervous System. | Pharmaceuticals (Basel) | 2024 | https://conductscience.org/library/papers/38399380 | PubMed |
| 14 | 32,435,421 | Novel Dithiolane-Based Ligands Combining Sigma and NMDA Receptor Interactions as Potential Neuroprotective Agents. | ACS Med Chem Lett | 2020 | https://conductscience.org/library/papers/32435421 | PubMed |
| 15 | 21,092,190 | The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine. | Mol Cancer | 2010 | https://conductscience.org/library/papers/21092190 | PubMed |
| 16 | 34,628,236 | Optimization of bifunctional piperidinamide derivatives as σ1R Antagonists/MOR agonists for treating neuropathic pain. | Eur J Med Chem | 2021 | https://conductscience.org/library/papers/34628236 | PubMed |
| 17 | 29,287,249 | Multifunctional thiosemicarbazones and deconstructed analogues as a strategy to study the involvement of metal chelation, Sigma-2 (σ2) receptor and P-gp protein in the cytotoxic action: In vitro and in vivo activity in pancreatic tumors. | Eur J Med Chem | 2018 | https://conductscience.org/library/papers/29287249 | PubMed |
| 18 | 1,469,697 | Radiosynthesis, cerebral distribution, and binding of [125I]-1-(p-iodophenyl)-3-(1-adamantyl)guanidine, a ligand for sigma binding sites. | J Med Chem | 1992 | https://conductscience.org/library/papers/1469697 | PubMed |
| 19 | 12,831,995 | Preclinical acute toxicity studies and rodent-based dosimetry estimates of the novel sigma-1 receptor radiotracer [(18)F]FPS. | Nucl Med Biol | 2003 | https://conductscience.org/library/papers/12831995 | PubMed |
| 20 | 24,337,599 | Evaluation of σ-1 receptor radioligand 18F-FTC-146 in rats and squirrel monkeys using PET. | J Nucl Med | 2014 | https://conductscience.org/library/papers/24337599 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,226,254 | A Full-Spectrum Evaluation of Sigma-1 Receptor (S1R) Positron Emission Tomography (PET) Radioligands from Binding Affinity to Clinical Imaging. | Molecules | 2025 | https://conductscience.org/library/papers/41226254 | PubMed |
| 40,956,957 | Targeting the Milieu in Neurodegenerative Disease: Time for "Imprecision Medicine"? | Aging Dis | 2025 | https://conductscience.org/library/papers/40956957 | PubMed |
| 40,888,353 | Prediction of Activity and Selectivity Profiles of Sigma Receptor Ligands Using Machine Learning Approaches. | J Chem Inf Model | 2025 | https://conductscience.org/library/papers/40888353 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| SIGMAR1 | 10,280 | PubTator's text mining | https://conductscience.org/library/genes/10280 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40242588
GET https://conductscience.org/api/papers/v1/40242588/references?page=2